상세 보기

Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies

Ma, W. W.;
Chung, I.;
Lang, I.;
Csoszi, T.;
Wenczl, M. W.;
... Kim, J. S.;
외 12명

제목: Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies

저자: Ma, W. W.; Chung, I.; Lang, I.; Csoszi, T.; Wenczl, M. W.; Cubillo, A.; Chen, J.; Wong, M.; Park, J. O.; Kim, J. S.; Rau, K. M.; Melichar, B.; Gallego, J.; Smakal, M.; Kim, J.; Belanger, B.; Bayever, E.; Adiwijaya, B.

DOI: 10.1016/S0959-8049(16)31281-3

발행일: 2015-09

학회명: European Cancer Congress

개최지: Vienna, AUSTRIA

개최국가: 영국

학회 개최일: 2015-09-25 ~ 2015-09-29

언어: ENG